Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV.
about
What happens to cardiovascular system behind the undetectable level of HIV viremia?Cardiovascular Disease, Statins, and HIVTreatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity.Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group StuInflammation, immune activation, and cardiovascular disease in HIV.Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but Does Not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral TherapyAltered Monocyte and Endothelial Cell Adhesion Molecule Expression Is Linked to Vascular Inflammation in Human Immunodeficiency Virus InfectionEquivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.Epidemiology of ischemic heart disease in HIV.Lipid Abnormalities and Inflammation in HIV Inflection.Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults.HIV-1-Associated Atherosclerosis: Unraveling the Missing Link.Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection.Baseline Vitamin D Deficiency Decreases the Effectiveness of Statins in HIV-Infected Adults on Antiretroviral Therapy.Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV.The Effect of Rosuvastatin on Vascular Disease Differs by Smoking Status in Treated HIV Infection.Effect of statin on arginine metabolites in treated HIV-infection.
P2860
Q26749024-BAE6BCB2-26E8-4FE0-8670-FFB09C8D1189Q30245373-F791841D-0573-4A86-8EEB-833D43F8F050Q33917580-14051379-5737-4F5E-B2CE-09236C051FE4Q36341298-0CA0D6C9-A821-44F6-B329-08E656716826Q36957752-071D0E91-663B-4D7F-8DA9-957F232BB63BQ37149855-64CD1BD3-463C-4364-8875-62D5A474281AQ37543675-A48A3506-61B8-46EE-9998-E33417D4C10AQ37604553-F22331BC-721D-4ADB-A6FA-3EDE8B344720Q38629009-459DC890-D77E-4A07-84C2-FB302D82BA54Q38849283-20F54D28-A5A0-4500-8D85-B26CB0ACEB3FQ39372824-5D4079AA-B2A4-4EFD-A611-70FA6708672DQ39392100-E5BA76CB-5663-425B-8D87-28B0A314FDF6Q39414284-5B599594-EFCB-4E5A-B37C-17B8ADCDBCF1Q40387290-33756523-7DAB-46E3-94FE-2AD90C97CC24Q40529577-9551FEFD-C3AC-4CA9-B5D3-68DA5A384847Q44360506-CED58DD1-0D1B-4812-A0AE-DC671035B757Q46911047-7876C094-3F29-4FDA-A491-1CF62A51072DQ50244544-3D5BF6E8-4452-4492-8715-ECE217A7F8ED
P2860
Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Changes in oxidized lipids dri ...... e after statin therapy in HIV.
@ast
Changes in oxidized lipids dri ...... e after statin therapy in HIV.
@en
type
label
Changes in oxidized lipids dri ...... e after statin therapy in HIV.
@ast
Changes in oxidized lipids dri ...... e after statin therapy in HIV.
@en
prefLabel
Changes in oxidized lipids dri ...... e after statin therapy in HIV.
@ast
Changes in oxidized lipids dri ...... e after statin therapy in HIV.
@en
P2093
P2860
P1433
P1476
Changes in oxidized lipids dri ...... e after statin therapy in HIV.
@en
P2093
Corrilynn O Hileman
Grace A McComsey
Randi Turner
P2860
P356
10.1097/QAD.0000000000000885
P407
P577
2016-01-01T00:00:00Z